Abstract | BACKGROUND & OBJECTIVE: High-dose conditioning regimens of chemo- radiotherapy with or without total body irradiation (TBI) frequently induces nausea and vomiting in patients who are supported with stem cell transplantation. 5-Hydroxytrypamine(3) (5-HT(3)) receptor antagonists, when used alone, are unsatisfactory in the attenuation of emesis; Furthermore, consensus about their optimal dose, optimal dosing frequency and the combined use with other anti-emetic drugs are still controversial. The main objective of this trial was to observe the anti-emetic effectiveness and side effects of tropisetron plus dexamethasone and diphenhydramine (Group A) and tropisetron alone (Group B) on the patients undergoing high-dose treatment for peripheral blood stem cell (PBSC) mobilization and transplantation. METHODS: From December 1998 to September 2002, 68 patients undergoing autologous peripheral blood stem cell transplantation were allotted into this study. All the eligible patients were divided into group A or B non-randomly to compare the efficacy of the two regimens in the prevention of nausea and vomiting induced by high-dose treatment. Regimens:40 patients in group A were given tropisetron 5 mg,iv,every 12 h plus dexamethasone 5-10 mg, iv, daily, and diphenhydramine, 20 mg, im, daily. Twenty-eight patients in group B were received tropisetron alone,5 mg,iv,every 12h. RESULTS: For nausea during the acute phase, complete response rates of group A and B were 55% and 46.4%, with an overall response rates of 97.5% and 85.7%,of which the difference was insignificant (P >0.05). For vomiting during the acute phase, complete response rates of group A and B were 77.5% and 78.6%, with an overall response rates of 90% and 92.9%, of which the difference was insignificant (P >0.05). For delayed phase, both the complete response and overall response rates were higher in group A, with the difference significant (P< 0.05). The side effects of both regimens were mild. Common side effects including abdomen discomfort, headache,heavy head and constipation did not necessitate the discontinuity of high-dose treatment. CONCLUSION:
|
Authors | Xiao-Hui He, Yuan-Kai Shi, Jian-Liang Yang, Chang-Gong Zhang, Peng Liu, Ai-Ping Zhou, Sheng-Yu Zhou, Bin Ai |
Journal | Ai zheng = Aizheng = Chinese journal of cancer
(Ai Zheng)
Vol. 23
Issue 4
Pg. 456-60
(Apr 2004)
China |
PMID | 15087039
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Child
- Combined Modality Therapy
- Female
- Humans
- Indoles
(adverse effects, therapeutic use)
- Male
- Nausea
(prevention & control)
- Neoplasms
(therapy)
- Peripheral Blood Stem Cell Transplantation
- Radiotherapy
(adverse effects)
- Transplantation, Autologous
- Tropisetron
- Vomiting
(prevention & control)
|